48 filings
Page 2 of 3
8-K
wdrq wu2a2h79yh
28 Jun 23
Results of Operations and Financial Condition
7:12am
8-K
803nc4
22 Jun 23
Other Events
7:30am
8-K
p1xco74ddevtmq t3p9
16 May 23
Other Events
8:30am
8-K
w9qvubpm
4 Apr 23
Other Events
7:56am
8-K
pjoiblalff17ga5h
16 Mar 23
Departure of Directors or Certain Officers
5:00pm
8-K
jnq zm87lhp
15 Mar 23
Roivant Reports Positive Topline Results from ADORING 2
7:51am
8-K
9tptoh
21 Feb 23
Departure of Directors or Certain Officers
4:02pm
8-K
b205m4t2dq4lfe9qxxd
13 Feb 23
Results of Operations and Financial Condition
7:18am
8-K
wujao3eve1cq0f2o0e
7 Feb 23
Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares
4:15pm
8-K
xcpp1rgnah28onz1y1ed
1 Feb 23
Results of Operations and Financial Condition
5:27pm
8-K
qfs13lwt62v8isn0
4 Jan 23
Other Events
6:11am
8-K
dccpsn7q
1 Dec 22
Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases
8:12am
8-K
6ahlh96xb
23 Nov 22
Departure of Directors or Certain Officers
5:15pm
8-K
m8s6za0kqel 9nyvbf4u
14 Nov 22
Expected cash runway extended into the second half of calendar year 2025
7:51am
8-K
vxr 393urez8
10 Nov 22
Roivant Sciences Announces Pricing of Primary and Secondary Public Equity Offering
4:07pm
8-K
d1iwv2rgc7cb1r
7 Nov 22
Roivant Sciences Announces Proposed Public Equity Offering
5:25pm
8-K
jahuev6ajlojibn uos
28 Sep 22
Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn
11:00am
8-K
dmffsxuymcgu
21 Sep 22
Termination of a Material Definitive Agreement
4:31pm
8-K
sx5qs83pmiwji63pxk
15 Aug 22
Results of Operations and Financial Condition
7:15am
8-K
c15tahdovue1uhiku
28 Jun 22
Results of Operations and Financial Condition
6:22am